Literature DB >> 3362949

A cumulative dosing procedure for administering marijuana smoke to humans.

L D Chait1, R L Corwin, C E Johanson.   

Abstract

Subjective, behavioral and physiological effects of smoked marijuana were measured with a cumulative dosing procedure which allowed dose-related effects to be determined within a single experimental session. Five male and three female occasional marijuana smokers participated. Unit doses of marijuana smoke were administered in a standardized manner on four occasions during each session, each occasion spaced 20 minutes apart. This procedure resulted in a cumulative dose of active (1.4%-THC) marijuana of 0, 2, 4 and 8 puffs after the four successive smoking occasions, respectively. Dependent variables were measured after each smoking occasion. Smoke absorption was monitored by measuring expired air carbon monoxide levels. Subjects participated in three identical sessions spaced a week apart in order to assess the reliability of the procedure. During a fourth session, only placebo (0.0%-THC) marijuana was administered throughout the session as a control. Significant linear dose-effect functions were obtained on several measures, with good session-to-session replicability of most effects. The results demonstrate the feasibility of using a cumulative dosing procedure to evaluate dose-related effects of smoked marijuana in humans. The procedure would be especially useful for the assessment of shifts in dose-effect curves as a result of various experimental manipulations.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3362949     DOI: 10.1016/0091-3057(88)90019-6

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  12 in total

1.  A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain.

Authors:  Barth Wilsey; Thomas Marcotte; Alexander Tsodikov; Jeanna Millman; Heather Bentley; Ben Gouaux; Scott Fishman
Journal:  J Pain       Date:  2008-04-10       Impact factor: 5.820

2.  Low-dose vaporized cannabis significantly improves neuropathic pain.

Authors:  Barth Wilsey; Thomas Marcotte; Reena Deutsch; Ben Gouaux; Staci Sakai; Haylee Donaghe
Journal:  J Pain       Date:  2012-12-11       Impact factor: 5.820

3.  Subjective and behavioral effects of marijuana the morning after smoking.

Authors:  L D Chait
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Comparing single and cumulative dosing procedures in human triazolam discriminators.

Authors:  B J Smith; W K Bickel
Journal:  J Exp Anal Behav       Date:  1999-05       Impact factor: 2.468

5.  Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance.

Authors:  L D Chait; J L Perry
Journal:  Psychopharmacology (Berl)       Date:  1994-07       Impact factor: 4.530

6.  Altered affective response in marijuana smokers: an FMRI study.

Authors:  Staci A Gruber; Jadwiga Rogowska; Deborah A Yurgelun-Todd
Journal:  Drug Alcohol Depend       Date:  2009-08-04       Impact factor: 4.492

7.  An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease.

Authors:  Barth Wilsey; Thomas D Marcotte; Reena Deutsch; Holly Zhao; Hannah Prasad; Amy Phan
Journal:  J Pain       Date:  2016-06-07       Impact factor: 5.820

8.  Progesterone effects on subjective and physiological responses to intravenous nicotine in male and female smokers.

Authors:  Mehmet Sofuoglu; Ellen Mitchell; Marc Mooney
Journal:  Hum Psychopharmacol       Date:  2009-10       Impact factor: 1.672

9.  Subjective responses to intravenous nicotine: greater sensitivity in women than in men.

Authors:  Mehmet Sofuoglu; Marc Mooney
Journal:  Exp Clin Psychopharmacol       Date:  2009-04       Impact factor: 3.157

10.  Effects of alcohol pretreatment on human marijuana self-administration.

Authors:  L D Chait; J L Perry
Journal:  Psychopharmacology (Berl)       Date:  1994-01       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.